Intensive Induction Therapy Compared to CHOP for Hepatosplenic T-cell Lymphoma

Hepatosplenic T-cell Lymphoma (HSTCL) is a rare peripheral T-cell lymphoma that disproportionately affects individuals with a clinical history of immunosuppression. It carries a poor prognosis, and due to its rarity, there is no single or well-established treatment.We conducted the largest-to-date individual-level meta-analysis based on literature searches to determine the best induction therapy for HSTCL. We compared response rates and survival among patients who received “non-CHOP-based” induction with regimens containing cytarabine, etoposide, and/or platinum-based treatment to those receiving treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 20, 2019 Category: Hematology Authors: Daniella Klebaner, Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Steven Horwitz, Aaron M. Goodman Tags: Original Study Source Type: research